| Species |
Human |
| Protein Construction |
MCP-4 (Gln24-Thr98)
Accession # Q99616 |
|
| Purity |
> 96% as analyzed by SDS-PAGE
> 96% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human monocytes is in a concentration of 10.0-100.0 ng/ml. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
8.6 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 20 mM PB, pH 7.4, 130 mM NaCl. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CCL13 is a chemoattractant for monocytes and eosinophils, and activates basophils. In addition, it has been reported to be chemotactic for CD4+ and CD8+ T cells, with an activity almost equivalent to that of MCP-3. The bioactivities of CCL13 is most likely mediated by the CC chemokine receptors CCR-2 and CCR-3, both of which have been shown to bind CCL13. |
| Synonyms |
SCYA13; MCP4; NCC-1; SCYL1; CKb10; CCL-13 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
